CASTLE BIOSCIENCES INC.
FRIENDSWOOD, TX

Castle Biosciences, Inc., established on May 12, 2017, is a pioneer in the field of molecular diagnostics focusing on cancer treatment decisions. Located at 505 S Friendswood Dr, Suite 401, The Woodlands, TX, Castle Biosciences develops and commercializes diagnostic and prognostic tests specifically designed to provide actionable, tumor-specific information that enhances treatment decisions and patient outcomes. Notably recognized for its groundbreaking test for uveal melanoma—a rare and aggressive eye cancer—Castle Biosciences' innovation has been widely adopted as the standard of care due to its superior accuracy in identifying high-risk metastatic cases compared to existing methods. This success led to successful reimbursement, exemplifying its model of practice-changing tests which also includes a prognostic assay for cutaneous (skin) melanoma. The company operates from a CLIA-certified and CAP-accredited clinical laboratory, ensuring the highest standards in diagnostic testing across several underserved cancer types with active development programs ongoing. Listed as an 'Other Business Corporation' in Florida under state law, Castle Biosciences' commitment to innovation is further supported by its leadership team comprising President Derek Maetzold, alongside Directors Daniel Bradbury and David Kabakoff. Castle Biosciences continues to expand its influence within oncology diagnostics with an unwavering focus on improving patient care through their cutting-edge technologies. For more information about their services and research initiatives, visit the company's website at castlebiosciences.com.